Skip to main content

Table 3 Recommendations Table: Mental health, quality of life, and life satisfaction

From: Consensus-based guidelines for the provision of palliative and end-of-life care for people living with epidermolysis bullosa

No.

Recommendation

Strength of recommendation

Key references*

General

R1

See R1 in Table 2 above

↑↑

[8, 9, 11,12,13,14,15,16,17,18,19]

 → [9, 10]

R36

Both the symptoms and treatments associated with EB require equal consideration when providing care necessitating that medical providers consider the whole person living with EB that is beyond the visible lesions

↑↑

 → [10]

[12, 24, 55,56,57]

R39

People living with EB must have the same opportunities to feel that they are a useful and contributing member of society as those individuals unaffected by EB by allowing them to grow emotionally, spiritually, and intellectually rather than holding them back because of any actual or perceived physical challenges that they may have

GPP

 

R41

Medical providers should help reduce the costs to the person living with EB and his/her family through judicious use of materials

↑↑

[62]

R44

Increasing public awareness of the biopsychosocial challenges caused by EB as well as addressing fears of contagion or abuse is necessary

↑↑

[13, 73]

R49

Health care providers should provide multi-faceted health care education to benefit patients and carers to encourage active engagement in the process of one’s own medical decision making throughout the lifespan

↑↑

[9, 13, 14, 16, 20, 23, 34, 43, 49]

R50

Established models for practice should be utilized

↑↑

[13, 16, 20, 34, 43, 49]

R51

Interventions provided by healthcare teams should target the development of personal support systems for people living with EB

↑↑

[15, 47, 49, 59, 87]

Patient, family, and carers mental health

R37

The mental health of parents, carers, and providers should be addressed

↑↑

 → [10]

[21, 47, 56,57,58,59,60]

R38

Focus should be placed on the emotional needs of the family and of the parent/child relationship

GPP

[59,60,61]

R40

Children living with EB should be encouraged to develop psychosocially and live their lives despite having EB while either accepting or distancing themselves from the disease

↑↑

 → [10]

[60]

R43

Formal and informal support and advocacy groups and solutions-focused psychotherapy, while being mindful of trauma, can help with coping related to EB, stigma, bullying loss, challenging decision-making, and bereavement while encouraging fuller participation in society, a sense of self-realization, having a fulfilling social life, and good peer support

↑↑

 → [10]

[48, 56,57,58, 60, 65, 72, 73]

R45

Family members need long-term support while helping to improve coping with the emotional burden associated with providing care and with bringing in respite

↑↑

 → [10]

R46

Psychological support of the person living with EB, their families, and carers is very important after a diagnosis of SCC, in end-of-life decision-making, or following bereavement

↑↑

 → [9]

Provider mental health

R34

See R34 in Table 2 above

↑↑

[10, 20, 47, 48]

Quality of life

R42

QoL and other psychological assessment/screening tools should be considered to help evaluate the impact of EB

↑↑

[13, 15, 16, 40, 50, 51, 55, 56, 59, 63,64,65,66,67,68,69,70,71]

R47

Involvement of an IDT (where each member has expertise in treating EB) that provides a wholistic treatment approach aids in the improvement of overall QoL, especially when the person living with EB decides their own therapeutic goals

↑↑

[2, 12, 13, 23, 26, 29, 32,33,34, 40, 53, 59, 61, 63, 74,75,76,77,78,79,80,81,82,83,84, 87]

R48

To improve QoL, symptoms should be managed through medical or surgical interventions

↑↑

 → [10, 26]

[23, 24, 27, 34, 35, 40, 84, 85]

  1. Recommendations are based on the results of the literature review. In addition, other recommendations relating to palliative care were added during the process of guideline development from expert consensus, and the experience of the guideline development group. To provide easier access to information, the recommendations in this table are grouped in accordance with the clinical questions and are arranged by clinical subheadings. If a recommendation fit within multiple subheadings or within multiple clinical questions, it was listed in each. Recommendations were not listed in order of strength or importance. Recommendation strength was strongly influenced by expert panel decision-making, which accounts for observable gaps between evidence levels and recommendation strength. The evidence level is very low for all recommendations. For the strength of recommendation ratings see Table 1. EB, epidermolysis bullosa; GPP, good practice point; G-tube, gastrostomy feeding tube; JEB, junctional epidermolysis bullosa; IDT, interdisciplinary team; QoL, quality-of-life; RDEB, recessive dystrophic epidermolysis bullosa; SCC, squamous cell carcinoma. *Right-pointing arrows (→) denote a guideline document